Discrepancy between low levels of mTOR activity and high levels of p-S6 in primary central nervous system lymphoma may be explained by PAS domain-containing serine/threonine-protein kinase-mediated phosphorylation

Dóra Marosvári, Noémi Nagy, Csilla Kriston, Beáta Deák, Melinda Hajdu, Csaba Bödör, Irén Csala, Attila G. Bagó, Zoltán Szállási, A. Sebestyén, Lilla Reiniger

Research output: Contribution to journalArticle

Abstract

The primary aim of this study was to determine mTOR-pathway activity in primary central nervous system lymphoma (PCNSL), which could be a potential target for therapy. After demonstrating that p-S6 positivity largely exceeded mTOR activity, we aimed to identify other pathways that may lead to S6 phosphorylation. We measured mTOR activity with immunohistochemistry for p-mTOR and its downstream effectors p(T389)-p70S6K1, p-S6, and p-4EBP1 in 31 cases of PCNSL and 51 cases of systemic diffuse large B-cell lymphoma (DLBCL) and evaluated alternative S6 phosphorylation pathways with p-RSK, p(T229)-p70S6K1, and PASK antibodies. Finally, we examined the impact of PASK inhibition on S6 phosphorylation on BHD1 cell line. mTOR-pathway activity was significantly less frequent in PCNSL compared with DLBCL. p-S6 positivity was related to mTOR-pathway in DLBCL, but not in PCNSL. Among the other kinases potentially responsible for S6 phosphorylation, PASK proved to be positive in all cases of PCNSL and DLBCL. Inhibition of PASK resulted in reduced expression of p-S6 in BHD1-cells. This is the first study demonstrating an mTOR independent p-S6 activity in PCNSL and that PASK may contribute to the phosphorylation of S6. Our findings also suggest a potential role of PASK in the pathomechanism of PCNSL and in DLBCL.

Original languageEnglish
Pages (from-to)268-273
Number of pages6
JournalJournal of Neuropathology and Experimental Neurology
Volume77
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

S 6
Protein-Serine-Threonine Kinases
Lymphoma
Central Nervous System
Phosphorylation
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Phosphotransferases
Immunohistochemistry

Keywords

  • mTOR
  • PASK
  • Primary central nervous system lymphoma (PCNSL)

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Discrepancy between low levels of mTOR activity and high levels of p-S6 in primary central nervous system lymphoma may be explained by PAS domain-containing serine/threonine-protein kinase-mediated phosphorylation. / Marosvári, Dóra; Nagy, Noémi; Kriston, Csilla; Deák, Beáta; Hajdu, Melinda; Bödör, Csaba; Csala, Irén; Bagó, Attila G.; Szállási, Zoltán; Sebestyén, A.; Reiniger, Lilla.

In: Journal of Neuropathology and Experimental Neurology, Vol. 77, No. 4, 01.04.2018, p. 268-273.

Research output: Contribution to journalArticle

Marosvári, Dóra ; Nagy, Noémi ; Kriston, Csilla ; Deák, Beáta ; Hajdu, Melinda ; Bödör, Csaba ; Csala, Irén ; Bagó, Attila G. ; Szállási, Zoltán ; Sebestyén, A. ; Reiniger, Lilla. / Discrepancy between low levels of mTOR activity and high levels of p-S6 in primary central nervous system lymphoma may be explained by PAS domain-containing serine/threonine-protein kinase-mediated phosphorylation. In: Journal of Neuropathology and Experimental Neurology. 2018 ; Vol. 77, No. 4. pp. 268-273.
@article{3f3fd157bb284d73a8015c6edd845521,
title = "Discrepancy between low levels of mTOR activity and high levels of p-S6 in primary central nervous system lymphoma may be explained by PAS domain-containing serine/threonine-protein kinase-mediated phosphorylation",
abstract = "The primary aim of this study was to determine mTOR-pathway activity in primary central nervous system lymphoma (PCNSL), which could be a potential target for therapy. After demonstrating that p-S6 positivity largely exceeded mTOR activity, we aimed to identify other pathways that may lead to S6 phosphorylation. We measured mTOR activity with immunohistochemistry for p-mTOR and its downstream effectors p(T389)-p70S6K1, p-S6, and p-4EBP1 in 31 cases of PCNSL and 51 cases of systemic diffuse large B-cell lymphoma (DLBCL) and evaluated alternative S6 phosphorylation pathways with p-RSK, p(T229)-p70S6K1, and PASK antibodies. Finally, we examined the impact of PASK inhibition on S6 phosphorylation on BHD1 cell line. mTOR-pathway activity was significantly less frequent in PCNSL compared with DLBCL. p-S6 positivity was related to mTOR-pathway in DLBCL, but not in PCNSL. Among the other kinases potentially responsible for S6 phosphorylation, PASK proved to be positive in all cases of PCNSL and DLBCL. Inhibition of PASK resulted in reduced expression of p-S6 in BHD1-cells. This is the first study demonstrating an mTOR independent p-S6 activity in PCNSL and that PASK may contribute to the phosphorylation of S6. Our findings also suggest a potential role of PASK in the pathomechanism of PCNSL and in DLBCL.",
keywords = "mTOR, PASK, Primary central nervous system lymphoma (PCNSL)",
author = "D{\'o}ra Marosv{\'a}ri and No{\'e}mi Nagy and Csilla Kriston and Be{\'a}ta De{\'a}k and Melinda Hajdu and Csaba B{\"o}d{\"o}r and Ir{\'e}n Csala and Bag{\'o}, {Attila G.} and Zolt{\'a}n Sz{\'a}ll{\'a}si and A. Sebesty{\'e}n and Lilla Reiniger",
year = "2018",
month = "4",
day = "1",
doi = "10.1093/jnen/nlx121",
language = "English",
volume = "77",
pages = "268--273",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Discrepancy between low levels of mTOR activity and high levels of p-S6 in primary central nervous system lymphoma may be explained by PAS domain-containing serine/threonine-protein kinase-mediated phosphorylation

AU - Marosvári, Dóra

AU - Nagy, Noémi

AU - Kriston, Csilla

AU - Deák, Beáta

AU - Hajdu, Melinda

AU - Bödör, Csaba

AU - Csala, Irén

AU - Bagó, Attila G.

AU - Szállási, Zoltán

AU - Sebestyén, A.

AU - Reiniger, Lilla

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The primary aim of this study was to determine mTOR-pathway activity in primary central nervous system lymphoma (PCNSL), which could be a potential target for therapy. After demonstrating that p-S6 positivity largely exceeded mTOR activity, we aimed to identify other pathways that may lead to S6 phosphorylation. We measured mTOR activity with immunohistochemistry for p-mTOR and its downstream effectors p(T389)-p70S6K1, p-S6, and p-4EBP1 in 31 cases of PCNSL and 51 cases of systemic diffuse large B-cell lymphoma (DLBCL) and evaluated alternative S6 phosphorylation pathways with p-RSK, p(T229)-p70S6K1, and PASK antibodies. Finally, we examined the impact of PASK inhibition on S6 phosphorylation on BHD1 cell line. mTOR-pathway activity was significantly less frequent in PCNSL compared with DLBCL. p-S6 positivity was related to mTOR-pathway in DLBCL, but not in PCNSL. Among the other kinases potentially responsible for S6 phosphorylation, PASK proved to be positive in all cases of PCNSL and DLBCL. Inhibition of PASK resulted in reduced expression of p-S6 in BHD1-cells. This is the first study demonstrating an mTOR independent p-S6 activity in PCNSL and that PASK may contribute to the phosphorylation of S6. Our findings also suggest a potential role of PASK in the pathomechanism of PCNSL and in DLBCL.

AB - The primary aim of this study was to determine mTOR-pathway activity in primary central nervous system lymphoma (PCNSL), which could be a potential target for therapy. After demonstrating that p-S6 positivity largely exceeded mTOR activity, we aimed to identify other pathways that may lead to S6 phosphorylation. We measured mTOR activity with immunohistochemistry for p-mTOR and its downstream effectors p(T389)-p70S6K1, p-S6, and p-4EBP1 in 31 cases of PCNSL and 51 cases of systemic diffuse large B-cell lymphoma (DLBCL) and evaluated alternative S6 phosphorylation pathways with p-RSK, p(T229)-p70S6K1, and PASK antibodies. Finally, we examined the impact of PASK inhibition on S6 phosphorylation on BHD1 cell line. mTOR-pathway activity was significantly less frequent in PCNSL compared with DLBCL. p-S6 positivity was related to mTOR-pathway in DLBCL, but not in PCNSL. Among the other kinases potentially responsible for S6 phosphorylation, PASK proved to be positive in all cases of PCNSL and DLBCL. Inhibition of PASK resulted in reduced expression of p-S6 in BHD1-cells. This is the first study demonstrating an mTOR independent p-S6 activity in PCNSL and that PASK may contribute to the phosphorylation of S6. Our findings also suggest a potential role of PASK in the pathomechanism of PCNSL and in DLBCL.

KW - mTOR

KW - PASK

KW - Primary central nervous system lymphoma (PCNSL)

UR - http://www.scopus.com/inward/record.url?scp=85045067079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045067079&partnerID=8YFLogxK

U2 - 10.1093/jnen/nlx121

DO - 10.1093/jnen/nlx121

M3 - Article

AN - SCOPUS:85045067079

VL - 77

SP - 268

EP - 273

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 4

ER -